The essence of the second stage is the RNA-dependent amplification of exogenous RdRp-compatible human AβPP mRNA and the resulting generation of iAβ in quantities sufficient to drive the AD pathology (and to perpetuate its own production). Here, APP is linked to Alzheimer disease.